Dr. Martens plc (DOCMF) Stock

About Dr. Martens plc

Dr. Martens plc is a global enterprise that manages the complete lifecycle of its footwear offerings. This includes everything from the initial design and development to the sourcing of materials, marketing, sales, and ultimate distribution of its products. The company's extensive reach covers Europe, the Middle East, Africa, the Americas, and the Asia-Pacific region. Its varied product range features popular "Originals," contemporary "Fusion" collections, children's footwear, and casual lines, in addition to a selection of accessories. All these goods are exclusively sold under the well-recognized Dr. Martens brand. Dr. Martens plc was established in 1945 and maintains its corporate headquarters in London, United Kingdom.

Dr. Martens plc is headquartered in GB.

Dr. Martens plc (DOCMF) stock trades at $1.14 with a market capitalization of $1.09B. The stock is valued at a price-to-earnings (P/E) ratio of 34.38, price-to-book of 2.27, price-to-sales of 1.07. Over the past 52 weeks the stock has ranged between $0.81 and $1.36, and currently trades 16.2% below its 52-week high. It pays a dividend yielding 4.39%.

On profitability, Dr. Martens plc generates a return on equity (ROE) of 6.89%, return on capital employed of 10.68%, an operating margin of 10.01%, a net profit margin of 3.11%.

Official website: www.drmartensplc.com

Dr. Martens plc by the numbers, 2017–2026

Between 2017 and 2026 Dr. Martens plc reported revenue of $291.0M rising to $767.0M, a change of +163.6% across 10 years. Compounded, revenue has grown -0.2% a year over five years, -8.5% over three, -2.7% over the last twelve months. Net profit rose to $24.0M.

Operating margin went from 11.4% in 2017 to 10.1% in 2026, a fall of 1.3 percentage points. The most recent net margin is 3.11%. On a trailing twelve-month basis to Mar '26, revenue is $1.6B and net profit $28.0M.

Borrowings held roughly flat from $391.0M to $392.0M, cash on hand is $180.8M, cash from operations was $126.0M in the latest year, positive in 10 of the last 10.

Return on equity has averaged 22.8% over five years, and was 6.6% in the most recent year.

The share price itself has compounded at -27.0% a year over five years, -14.6% over three, 13.3% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Dr. Martens plc (DOCMF) — frequently asked questions